Abstract
A number of kinesin proteins (KIFs) have been implicated in the development of multiple cancers. However, little is known about the expression and function of KIF15 in human breast cancer. Herein, we detected KIF15 expression in breast cancer tissues and paired adjacent normal tissues using immunohistochemistry and quantitative real-time polymerase chain reaction analysis, and the correlation of KIF15 expression with clinicopathological parameters was evaluated statistically. The role of KIF15 in cell proliferation, migration, tumor growth and metastasis of breast cancer cells was investigated in vitro and in vivo, and we explored potential molecular mechanisms underlying the effects of KIF15 in breast cancer through western blot analysis. The results revealed that increased KIF15 expression in breast cancer tissues were positively related with tumor size, lymph node metastasis and TNM stage, and higher KIF15 expression predicts a worse prognosis of patients with breast cancer. Furthermore, KIF15 knockdown markedly attenuated breast cancer cell proliferation, migration, tumor growth and metastasis in vitro and in vivo, and silenced KIF15 expression significantly inhibited the expression of phosphorylated AKT, phosphorylated JNK, and cyclin D1, while both p53 and p21 protein expressions were strongly enhanced. These results suggest that KIF15 is a potential oncogene in human breast cancer.
Similar content being viewed by others
Data availability
The data generated and analyzed in this study are available from the corresponding author on reasonable request.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.
Song D, Cui M, Zhao G, Fan Z, Nolan K, Yang Y, et al. Pathway-based analysis of breast cancer. Am J Transl Res. 2014;6(3):302–11.
Arango BA, Rivera CL, Gluck S. Gene expression profiling in breast cancer. Am J Transl Res. 2013;5(2):132–8.
Goulet A, Major J, Jun Y, Gross SP, Rosenfeld SS, Moores CA. Comprehensive structural model of the mechanochemical cycle of a mitotic motor highlights molecular adaptations in the kinesin family. Proc Natl Acad Sci USA. 2014;111(5):1837–42. https://doi.org/10.1073/pnas.1319848111.
Hirokawa N, Pfister KK, Yorifuji H, Wagner MC, Brady ST, Bloom GS. Submolecular domains of bovine brain kinesin identified by electron microscopy and monoclonal antibody decoration. Cell. 1989;56(5):867–78.
Vale RD, Reese TS, Sheetz MP. Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell. 1985;42(1):39–50.
Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol. 2005;15(9):467–76. https://doi.org/10.1016/j.tcb.2005.07.006.
Miki H, Setou M, Kaneshiro K, Hirokawa N. All kinesin superfamily protein, KIF, genes in mouse and human. Proc Natl Acad Sci USA. 2001;98(13):7004–111. https://doi.org/10.1073/pnas.111145398.
Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science. 1998;279(5350):519–26.
Hirokawa N, Noda Y, Tanaka Y, Niwa S. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol. 2009;10(10):682–96. https://doi.org/10.1038/nrm2774.
Wordeman L. How kinesin motor proteins drive mitotic spindle function: lessons from molecular assays. Semin Cell Dev Biol. 2010;21(3):260–8. https://doi.org/10.1016/j.semcdb.2010.01.018.
Liu X, Gong H, Huang K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci. 2013;104(6):651–6. https://doi.org/10.1111/cas.12138.
Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishimura H, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007;13(22 Pt 1):6624–31. https://doi.org/10.1158/1078-0432.CCR-07-1328.
Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, Rao PH, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosom Cancer. 2007;46(4):373–84. https://doi.org/10.1002/gcc.20418.
Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle. 2007;6(1):70–4. https://doi.org/10.4161/cc.6.1.3682.
Liu X, Li Y, Zhang X, Liu XY, Peng A, Chen Y, et al. Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule-targeting agents by blocking cytokinesis. Cancer Sci. 2018;109(11):3450–60. https://doi.org/10.1111/cas.13794.
Asbaghi Y, Thompson LL, Lichtensztejn Z, McManus KJ. KIF11 silencing and inhibition induces chromosome instability that may contribute to cancer. Genes Chromosomes Cancer. 2017;56(9):668–80. https://doi.org/10.1002/gcc.22471.
Drechsler H, McHugh T, Singleton MR, Carter NJ, McAinsh AD. The Kinesin-12 Kif15 is a processive track-switching tetramer. eLife. 2014;3:e01724. https://doi.org/10.7554/eLife.01724.
Tanenbaum ME, Macurek L, Janssen A, Geers EF, Alvarez-Fernandez M, Medema RH. Kif15 cooperates with eg5 to promote bipolar spindle assembly. Curr Biol. 2009;19(20):1703–11. https://doi.org/10.1016/j.cub.2009.08.027.
Wang J, Guo X, Xie C, Jiang J. KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. Br J Cancer. 2017;117(2):245–55. https://doi.org/10.1038/bjc.2017.165.
Qiao Y, Chen J, Ma C, Liu Y, Li P, Wang Y, et al. Increased KIF15 Expression predicts a poor prognosis in patients with lung adenocarcinoma. Cell Physiol Biochem. 2018;51(1):1–10. https://doi.org/10.1159/000495155.
Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res. 2014;12(4):539–49. https://doi.org/10.1158/1541-7786.MCR-13-0459.
Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28. https://doi.org/10.1146/annurev-med-062913-051343.
Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol. 2014;171(1):24–37. https://doi.org/10.1111/bph.12432.
Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94(12):1313–26. https://doi.org/10.1007/s00109-016-1475-3.
El-Deiry WS. p21(WAF1) Mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Can Res. 2016;76(18):5189–91. https://doi.org/10.1158/0008-5472.CAN-16-2055.
Yang L, Zhao W, Wei P, Zuo W, Zhu S. Tumor suppressor p53 induces miR-15a processing to inhibit neuronal apoptosis inhibitory protein (NAIP) in the apoptotic response DNA damage in breast cancer cell. Am J Transl Res. 2017;9(2):683–91.
Song X, Zhang T, Wang X, Liao X, Han C, Yang C, et al. Distinct diagnostic and prognostic values of kinesin family member genes expression in patients with breast cancer. Med Sci Monit. 2018;24:9442–644. https://doi.org/10.12659/MSM.913401.
Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2008;26(3):249–55. https://doi.org/10.1007/s10637-007-9097-9.
Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer. 2012;12(8):527–39. https://doi.org/10.1038/nrc3310.
Acknowledgements
This work was supported by grants from the Suzhou Health Planning Commission’s Key Clinical Diagnosis and Treatment Program (LCZX201606), National Natural Science Foundation of China (81873730) and the Jiangsu Women and Children Health Key Discipline Program (FXK201758).
Funding
This work was supported by grants from the Suzhou Health Planning Commission’s Key Clinical Diagnosis and Treatment Program (LCZX201606), National Natural Science Foundation of China (81873730) and the Jiangsu Women and Children Health Key Discipline Program (FXK201758).
Author information
Authors and Affiliations
Contributions
JG: project supervision, revision, and approval; GX and ZL: data collection, management and analysis; LX and WY: data analysis and critical revision; LR: statistical analysis; GX and JG: paper writing and editing.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
This study was approved by the Human Research Ethics Committees at the Second Affiliated Hospital of Soochow University, China. The approval number is JD-LK-2018-009-02. All the participants signed written informed consent forms. All animal experiments were performed according to the protocols approved by the Medical Experimental Animal Care Commission of Soochow University.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gao, X., Zhu, L., Lu, X. et al. KIF15 contributes to cell proliferation and migration in breast cancer. Human Cell 33, 1218–1228 (2020). https://doi.org/10.1007/s13577-020-00392-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13577-020-00392-0